|By PR Newswire||
|September 3, 2014 08:45 AM EDT|
ROCKVILLE, Md., Sept. 3, 2014 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it received a payment of $1 million, representing the last tranche of a $2.5 million product license and securities purchase agreement with G-treeBNT Co., Ltd, to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate in the U.S. G-treeBNT purchased 8,333,333 shares of common stock at $0.12 per share and retains an option until January 31, 2015 to purchase additional common stock for $825,000 at $0.15 per share. The licensing and securities purchase agreements have previously been filed as exhibits to the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2014.
Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements concerning the development and potential future commercialization of RGN-137 and RGN-259, and possible future milestone payments or exercise of G-treeBNT's equity option. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. There can also be no assurance that any license agreement or product development program undertaken by RegeneRx or its licensees will be commercially successful. Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2013, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.
SOURCE RegeneRx Biopharmaceuticals, Inc.
Discussions about cloud computing are evolving into discussions about enterprise IT in general. As enterprises increasingly migrate toward their own unique clouds, new issues such as the use of containers and microservices emerge to keep things interesting. In this Power Panel at 16th Cloud Expo, moderated by Conference Chair Roger Strukhoff, panelists will address the state of cloud computing today, and what enterprise IT professionals need to know about how the latest topics and trends affec...
May. 23, 2015 11:45 AM EDT Reads: 1,028
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading in...
May. 23, 2015 11:30 AM EDT Reads: 2,281
May. 23, 2015 11:15 AM EDT Reads: 1,549
May. 23, 2015 11:00 AM EDT Reads: 3,698
May. 23, 2015 11:00 AM EDT Reads: 1,349
May. 23, 2015 11:00 AM EDT Reads: 633
May. 23, 2015 11:00 AM EDT Reads: 5,364
May. 23, 2015 10:45 AM EDT Reads: 1,495
May. 23, 2015 10:30 AM EDT Reads: 2,610
May. 23, 2015 10:00 AM EDT Reads: 2,852
May. 23, 2015 10:00 AM EDT Reads: 5,234
May. 23, 2015 10:00 AM EDT Reads: 1,747
May. 23, 2015 10:00 AM EDT Reads: 902
May. 23, 2015 10:00 AM EDT Reads: 1,269
May. 23, 2015 10:00 AM EDT Reads: 1,640